SCHEMBL10243841

SCHEMBL10243841

COC(=O)NCCNC(C)c1cc(O)cc(O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 5/20 0.39
TSHR P16473 2/20 0.39
HIF1A Q16665 1/20 0.39
ADRA1A P35348 1/20 0.39
LMNA P02545 2/20 0.38
MEN1 O00255 1/20 0.38
APEX1 P27695 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
HSP90AB1 P08238 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
CA14 Q9ULX7 2/20 0.37
RRM1 P23921 1/20 0.36
EPHX1 P07099 1/20 0.35
CD274 Q9NZQ7 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243848 0.85 OPRK1 (0.44) ADRB2TSHRHIF1AADRA1ALMNA
SCHEMBL10243804 0.85 OPRK1 (0.44) ADRB2TSHRHIF1AADRA1ALMNA
SCHEMBL10244285 0.84 ESR1 (0.42) ADRB2HIF1AADRA1ALMNACA12
SCHEMBL10244110 0.84 KMT2A (0.40) LMNAMEN1KMT2ACA12CA1
SCHEMBL10244522 0.78 RRM1 (0.42) TSHRLMNARRM1CD274SMN1; SMN2
SCHEMBL10244323 0.77 SLC22A3 (0.51) TSHRLMNABLMFOLH1
SCHEMBL10243936 0.77 CA12 (0.40) TSHRMEN1KMT2ACA12CA1
SCHEMBL10243687 0.76 CASR (0.56) MEN1KMT2ASMN1; SMN2SLC6A2
SCHEMBL10243724 0.75 KMT2A (0.44) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL10243996 0.75 CASR (0.42) TSHRMEN1KMT2ARRM1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ADRB2 4378/4885TSHR 1567/4885HIF1A 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.